Open AccessMore Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
Author(s) -
Frederic R. Curtiss
Publication year - 2006
Publication title -
journal of managed care pharmacy
Language(s) - English
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2006.12.4.343
Subject(s) - montelukast , medicine , asthma , leukotriene , value (mathematics) , intensive care medicine , clinical trial , machine learning , computer science